Latest: Q3 2026 · from the cash-flow statements filed with the SEC
Free cash flow$133M in Q3 2026 · $337M over twelve months
Operating cash flow$151M
Capital spending−$18.5M
Free cash flow+$133M
Cash / net income2.6×
Cash conversion cycle131 days
Analysis
In Q3 2026, Herbalife generated $151M of operating cash flow and spent $18.5M on capital projects, leaving free cash flow of $133M. That is $14.8M more than in Q3 2025 ($118M).
Over the twelve months to Sep 30, 2026, operating cash flow was $396M; the largest uses were net borrowing (+) / repaid (−) ($129M), other financing ($64.3M), capital spending ($59.2M); the cash balance rose by $104M.
Operating cash flow was $151M against net income of $57.1M — 2.6× profit, cash ran ahead of reported earnings. The largest differences: other liabilities +$46.2M, depreciation & amortization +$30.5M, prepaid and other assets −$20.3M.
Its cash conversion cycle was 131 days (receivables 8 + inventory 153 − payables 29).
Free cash flow
Operating cash flow less capital spending.Latest (Q3 2026): Operating cash flow $151M, Capital spending $18.5M.
Capital allocation, year by year
Over these 5 years operating cash flow totalled $1.8B; the largest uses were net borrowing ($1.5B) and buybacks ($1.2B). Cash-flow statements as filed.
Cash runway and the debt wall
Cash & investments$409M
Debt$1.9B
Net debt$1.5B
Due within a year$20.9M
Herbalife funds itself: free cash flow was $337M over the last twelve months, and $409M of cash and investments stands against $1.9B of debt ($20.9M due within a year, 19.6× covered by cash).
Principal due in each year as disclosed in the annual report, against $409M of cash and investments now.
Where the cash came from and went
From profit to cash
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
Quarter
Receivable days
Inventory days
Payable days
Cash conversion cycle
Q3 2026
8
153
29
131
Q2 2026
8
154
29
132
Q1 2026
7
156
29
133
Q4 2025
7
163
30
140
Q3 2025
7
166
29
144
Q2 2025
7
164
29
142
Q1 2025
6
163
26
143
Q4 2024
6
170
27
149
Every quarter
Quarter
Operating cash flow
Capital spending
Buybacks
Net borrowing (+) / repaid (−)
Cash drawn (+) / kept (−)
Free cash flow
Q3 2026
$151M
−$18.5M
−$200K
−$88.2M
−$38.7M
$133M
Q2 2026
$32.9M
−$11.3M
−$9.3M
−$5.2M
$79.6M
$21.6M
Q1 2026
$114M
−$10.9M
−$700K
−$5.2M
−$97.7M
$103M
Q4 2025
$98.3M
−$18.5M
−$100K
−$30.2M
−$47.3M
$79.8M
Q3 2025
$139M
−$20.8M
−$1.3M
−$128M
$15.6M
$118M
Q2 2025
$96.0M
−$22.8M
−$4.6M
−$56.0M
$7.4M
$73.2M
Q1 2025
$200K
−$18.3M
−$2.2M
−$70.3M
$87.1M
−$18.1M
Q4 2024
$69.6M
−$25.7M
−$2.6M
−$10.3M
−$20.2M
$43.9M
Herbalife: income statement and cash flow
Herbalife, Q3 2026: revenue $1.4B (+6% year over year), operating margin 10.3%. The chart follows the revenue to costs, profit and cash.
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.